Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1841MR)

This product GTTS-WQ1841MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1841MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13579MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ5667MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ9205MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ2994MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ15206MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ11380MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ5525MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ3972MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW